Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease
Autor: | Kiyohide Fushimi, Hiroyo Kuwabara, Akihito Uda, Sayuri Shimizu, Ryuichi Iwakiri |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Combination therapy RC799-869 Lower risk Gastroenterology 03 medical and health sciences 0302 clinical medicine Intestinal Stricture Internal medicine Medicine Survival analysis antitumor necrosis factor alpha Crohn's disease Hepatology business.industry Hazard ratio steroid intestinal strictures Retrospective cohort study immunomodulator Original Articles Diseases of the digestive system. Gastroenterology medicine.disease Confidence interval 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Original Article observational study business |
Zdroj: | JGH Open: An Open Access Journal of Gastroenterology and Hepatology JGH Open, Vol 4, Iss 3, Pp 532-540 (2020) |
ISSN: | 2397-9070 |
Popis: | Background and Aim Intestinal strictures in Crohn's disease (CD) have a high rate of repeated surgery. As alternatives to surgery, endoscopic balloon dilatation (EBD), immunomodulators (IMs), and antitumor necrosis factor alpha (anti‐TNFα) have been proposed. We aimed to assess the effectiveness of the combined therapy with anti‐TNFα and EBD in preventing intestinal stricture recurrence and surgery in patients with CD. Methods This retrospective cohort study included patients from the nationwide administrative database in Japan who were hospitalized and underwent at least one EBD between 1 April 2010 and 31 March 2017. The effectiveness of anti‐TNFα was evaluated by performing survival analysis for the primary outcome. We selected the inverse probability of treatment weighting method for adjustment of covariates. As an exploratory analysis, we evaluated the association of anti‐TNFα initiation timing with intestinal stricture recurrence. Results The anti‐TNFα exposed group had a significantly lower risk of intestinal stricture recurrence than that of the anti‐TNFα nonexposed group (hazard ratio = 0.38, 95% confidence interval 0.31–0.48, P The combined therapy with anti‐TNFα and EBD could have preventive effects for intestinal stricture recurrence and surgery in hospitalized patients with CD. Particularly, anti‐TNFα initiation may be recommended before or after EBD, not immediately after EBD. With respect to EBD, it is important to clarify the effectiveness of combination therapy with several new medication treatments, such as biologics. |
Databáze: | OpenAIRE |
Externí odkaz: |